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Abstract 
Closely linking genetics and environment factors, epigenetics has been of increasing interest in 
psychiatric disease studies. In this work, we integrated single nucleotide polymorphisms (SNPs), DNA 
methylation of blood and saliva, and brain gray matter (GM) measures to explore the role of genetic and 
epigenetic variation to the brain structure changes in schizophrenia (SZ). By focusing on the reported SZ 
genetic risk regions, we applied a multi-stage multivariate analysis to a discovery dataset (92 SZ patients 
and 110 controls, blood) and an independent replication dataset (93 SZ patients and 99 controls, saliva).  
Two pairs of SNP-methylation components were significantly correlated (r=0.48 and 0.35) in blood 
DNA, and replicated (r=0.46 and 0.29) in saliva DNA, reflecting cross-tissue SNP cis-effects. In the 
discovery data both SNP-related methylation components were also associated with one GM component 
primarily located in cerebellum, caudate and thalamus. Additionally, another methylation component in 
NOSIP gene with significant SZ patient differences (p=0.009), was associated with eight GM components 
(seven with patient differences) including superior, middle, and inferior frontal gyri, superior, middle, and 
inferior temporal gyri, cerebellum, insula, cuneus, and lingual gyrus. Of these, five methylation-GM 
associations were replicated (p<.05). In contrast, no pairwise significant associations were observed 
between SNP and GM components.  
This study strongly supports that compared to genetic variation, epigenetics show broader and more 
significant associations with brain structure as well as diagnosis, which can be cross tissue, and the 
potential in explaining the mechanism of genetic risks in SZ.  
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Introduction 
Schizophrenia (SZ) is a highly heritable complex disease with a lifetime prevalence of around 1%1-3. 
Recent landmark work from the psychiatric genomics consortium (PGC) has identified 128 genome-wide 
significant SZ-risk SNPs4 from 108 highly linkage genomic regions (R2>0.6), providing reliable guidance 
for investigating the etiology and pathophysiology of schizophrenia. 
To uncover the biological mechanisms of such SZ-risk variants , a valuable strategy is to explore 
the genetic influence on brain-based phenotypes through magnetic resonance imaging (MRI) techniques5. 
Imaging-derived structural or functional measures of the brain (e.g., gray matter density) have been 
shown to be reliable and highly heritable6-8. Considerable success in the imaging genetics field has 
enriched our understanding of the putative neurobiological pathways from genetic mutations to system 
level and behavioral changes resulting in psychiatric disorders9-12. However, a recent study of genetic 
influences on SZ and subcortical brain volumes found no clear evidence of shared genetic variants13. 
Although this study is limited to the selected subcortical regions, it suggests that more complex biological 
pathways may involve bridging the gap from DNA variation to brain system changes in SZ.  
Epigenetics, beyond genetic sequence variation, regulates gene expression and thus influences 
biological functions14,15. Epigenetics can be modulated by genetics16, potentially mediating genetic risks17, 
and also integrate environmental factors in the etiopathogenesis of SZ18-20. DNA methylation, as one of 
the main epigenetic modifications, has shown to be related to SZ symptoms21, disease onset22, cognitive 
deficit23, and be significantly changed in schizophrenic brain24,25 and peripheral tissues26. Although 
methylation tends to be tissue specific in general, recent studies have noted a set of methylation sites 
significantly correlated between blood and brain27-29. This cross-tissue mechanism is hypothesized to be 
through genetics, called methylation quantitative trait loci (meQTL) effect30,31. In parallel, accumulating 
evidence has shown the relationship of peripheral DNA methylation with brain structure and function23,32-
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35. These findings support the potential of peripheral methylation in association with brain structure or 
function to further understand psychiatric disorders.     
Two recent studies have demonstrated the significant role of meQTL in brain development and 
SZ31,36. However, the underlying mechanisms of how epigenetic factors interplay with genetic factors, and 
further influence brain structural variation and psychiatric disorders are far from clear. In this study, we 
explored the interconnections between the three modalities -single nucleotide polymorphisms(SNPs), 
DNA methylation from blood and saliva, and whole brain gray matter (GM)- from SZ patients and 
healthy controls (HCs) in two independent datasets. We focused on SNPs and methylation sites within the 
108 SZ-risk regions identified by PGC4. Given the dependence of loci in both genotype and methylation, 
a multivariate analysis based on parallel independent component analysis (ICA)37, which has been 
suggested to identify clusters of correlated loci in genetic applications38,39, was performed to capture the 
intrinsic genetic-epigenetic relationships. Brain networks were extracted by ICA using GM images from 
structural MRI40. Finally, we tested the relationships among components of three modalities, as well as 
their associations with clinical diagnosis, symptoms, and cognition.  
Methods and Materials  
More details of methods and materials were provided in the supplementary information (SI Materials and 
Methods). 
Participants 
The discovery dataset consisted of 202 subjects recruited by the Mind Clinical Imaging Consortium 
study41. Patients met criteria for DSM-IV-TR schizophrenia, schizoaffective, or schizophreniform 
disorders. Healthy controls had no current or past history of psychiatric illness including substance abuse 
or dependence. Following a similar recruitment protocol, the replication data were collected from the 
Center for Biomedical Research Excellence study42 and Glutamate and Outcome in Schizophrenia 
study43. All participants of these studies as shown in Table 1 provided written consent forms.     
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In the discovery data symptoms were assessed with the Scale of the Assessment of Positive 
Symptoms44 and the Scale of the Assessment of Negative Symptoms45. Alcohol abuse/dependence status 
was assessed by DSM-IV and 101 participants provided reliably nicotine use information measured by 
pack per year46. In the replication data, participants had no current diagnosis of alcohol abuse or 
dependence, and nicotine use was assessed by Fagerstrom Test for Nicotine Dependence47. For the 
cognitive assessment, we focused on two comparable tests between studies: 1) letter-number sequencing 
test of the WAIS-III and MATRICS for measuring working memory48,49, and 2) computerized version of 
the Tower of London(TOL) test50 and the NAB maze test51 for measuring planning and problem solving. 
 
Data preprocessing 
DNA was extracted from whole blood in the discovery data. Genotyping was performed using the 
Illumina Infinium HumanOmni1-Quad assay. Data was quality controlled including checking for missing 
data, sex mismatch, relatedness, Hardy-Weinberg Equilibrium(<1×10-6), minor allele frequency(>0.01) 
and population structure correction. DNA methylation was assayed by the Illumina Infinium 
HumanMethylation27 assay. Quality control included removal of bad samples and probes, batch 
correction, and removal of non-variant sites. Age and gender were further adjusted by linear regression 
model.  Finally, we narrowed down our analyses to the 108 SZ-susceptible regions4, resulting in 4,475 
SNPs and 102 cytosine-phosphate-guanine(CpG) sites.  
Saliva samples were used for DNA extraction in the replication data.  Genotyping was performed 
using both Illumina Infinium HumanOmni1-Quad and Omni5 assays. The SNP data was quality 
controlled by following the same procedure as that in MCIC data. Missing genotypes were imputed with 
the 1000 genomes reference panel. DNA methylation was assayed by the Infinium MethylationEPIC 
beadchip. Quality control was performed using package ‘minfi’52. Batch, age and gender were adjusted on 
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each site prior to analysis. Cell type proportions in blood and saliva samples were estimated using the 
algorithm by Houseman et.al53.  
T1-weighted MRI images in both datasets were preprocessed using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). Unmodulated gray matter images were smoothed by 
a full width half maximum Gaussian kernel of 8 mm, followed by the correction for scanning sites (for 
the discovery data), age and gender on each voxel as suggested in previous studies54,55. No significant 
differences on GM networks were observed when using modulated images (data not shown).  
 
Primary analysis 
A multi-level association analysis was applied as shown in Fig.1. Parallel ICA was first applied to SNP 
and DNA methylation data to derive independent genetic and methylation components, while maximizing 
inter-modality correlations of the components’ loadings. Independent components of each modality were 
linear combinations of individual variants, capturing interactions among SNPs or CpG sites. A loading 
vector presented the expression of each component across subjects. Ten-fold subsample and permutation 
tests were conducted to verify the stability and significance of the SNP-methylation component links. For 
the linked SNP-methylation components, meQTL analysis was applied to the contributing SNPs and CpG 
sites to verify SNP effect on methylation at individual site level. In parallel, independent GM components 
were derived by a regular ICA on whole brain GM images. Then, the SNP and methylation components 
were tested for associations with GM components using a linear regression model. For any three-modality 
links, a mediation model was further tested for the methylation component mediating the genetic 
component’s effect on the GM component. In addition, all SNP, methylation and GM components were 
tested for the associations with diagnosis, symptoms, and cognition to help elucidate their relation to 
schizophrenia disease. Medication, cell type proportion, alcohol abuse and smoking were also assessed 
with their influences on the results as additional covariates in regression model. All the tests were 
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corrected for multiple comparison using the false discovery rate (FDR<=.05)56. For replication, we 
extracted the same SNP, methylation and GM components identified in the discovery data using a 
projection method and assessed their associations. The significance p<0.05 and the same direction of 
correlation were set for replication.  
Results 
SNP, DNA methylation components and inter-modality relationship 
In the discovery data, 15 SNP components and 10 methylation components were extracted. Among them, 
three methylation components, but no SNP component showed significant disease association. After 
correction for multiple comparisons, two pairs of SNP-methylation components were significantly 
correlated with r=0.48 (p=5.46×10-11) and 0.35 (p=3.28×10-5). The correlations were consistent in ten-
fold stability tests with the average correlations of 0.50±0.04 and 0.25±0.11, respectively. No significant 
effects of race and alcohol abuse were observed on the SNP-methylation associations. Permutation tests 
showed the significance of the two links with empirical p-values of 1×10-3 and 0.01.    
Fig.2(B,E) shows the loadings of the two pairs of SNP and methylation components across 
subjects. Both pairs indicated increased SNP loading along with the higher methylation loading. A higher 
loading indicates more presentation of positively weighted SNPs, and hyper-methylation of positively 
weighted CpG sites. The HC and SZ groups exhibited comparable correlations for both pairs (1st pair: 
0.49 and 0.46; 2nd pair: 0.39 and 0.23), respectively.  Excluding the schizoaffective and schizophreniform 
patients did not change the correlation by much. Marginal group differences were found in components of 
the second pair (psnp=0.09, pmethylation=0.04, uncorrected). After correcting for clinical diagnosis, the SNP-
methylation associations remained significant for both pairs (p=4.41×10-10, and 2.36×10-4). By 
thresholding the contribution weights of loci in the components with |z-score|>2.5, there were 94 
significant SNPs from 20 genes or their nearby regions in the first linked SNP component (Table S1), and 
five CpG sites in the genes NT5C2, CSMD1, FES, and ARL3 in the corresponding methylation 
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component. In the second pair, 60 highly weighted SNPs from 19 genes and one CpG site in the gene 
ITIH4 were involved in the correlation (Table S2).  
meQTL analysis on the contributing SNPs and CpG sites found 69 meQTLs in the first pair and 
59 meQTLs in the second pair after FDR correction, mostly showing cis effects (SNP effect of CpG site 
within 500kbp distance31). In the first pair cis-acting meQTLs were located on chromosome 10 around 
three CpG sites in NT5C2 and ARL3 (Fig.2A), where the strongest cis-effect resides in SNP rs1926030 
and CpG cg00035347 with partial η2 (% of variance explained) =50.3%, p=3.6×10-32 (Fig.2C), indicating 
that an increasing minor allele A count in rs1926030 was associated with hypomethylation at cg00035347 
located in the promoter of NT5C2. The cis-effecting meQTLs in the second pair was found in 
chromosome 3 around ITHI4 (Fig.2D). The strongest meQTL effect was between SNP rs2071041 and 
CpG cg17890764 with partial η2 = 13.9%, p=4.5×10-8 (Fig.2F). Other meQTL relations were listed in 
Tables S3 and S4. Overall, the cis-effecting meQTLs strongly affected the methylation change (partial η2 
median value: 10.88%, interquartile change IQR: 6.95%-21.24%). 
We further compared our meQTLs with two recent meQTL studies in fetal31 and adult brain 
tissues36. Among 69 meQTLs identified in the first SNP-methylation pair, 14 were also separately 
identified in both brain tissues with 12 in common. For the 59 meQTLs in the second pair, 13 were found 
in the fetal brain tissue and 11 were in adult brain tissue with 7 in common.  
In the replication data 72.21% of SNPs and 52% of methylation sites used in the discovery data 
were present, including over 96% of contributing loci and CpG sites (|z|>2.5) in the identified significant 
SNP-methylation pairs. The replicated correlations for the two linked SNP-methylation pairs were r=0.46, 
p=1.59×10-11 and r=0.29, p=5.9×10-5, respectively, and the correlations (r=0.53, p=4.93×10-8; r=0.26, 
p=1.08×10-2) were consistent in SZ group only (no significant difference after excluding schizoaffective 
patients). In the first SNP-methylation pair, 72 meQTLs were identified including 67 (97.1%) found in 
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the discovery set. Similarly, for the second SNP-methylation pair, 57 meQTLs were identified and 
replicated 98.28% meQTLs in the discovery data. 
GM components and their associations with DNA methylation 
GM data were decomposed into 15 independent components by ICA, of which 10 components showed 
significant associations with diagnosis (Fig.S2). Nine components (Fig.3) were significantly associated 
with three methylation components, as listed in Table 2. Interestingly, seven out of nine GM components 
showed significant group differences, and remained significant after controlling for alcohol abuse except 
component 7 with p=0.06. It was worth noting that in the GM components 1 and 2 with the largest group 
differences, SZ patients showed substantial GM loss in the areas of superior/middle/medial/inferior 
frontal gyri, and superior/middle/inferior temporal gyri. 
Among the three methylation components, methylation component 1, mainly involving the 
NOSIP gene, showed a significant group difference (Cohen’s d = -0.348; p =0.009). Consistently, the 
CpG site (cg05696092) located in the gene promoter region was hypomethylated in SZ (p= 6.4×10-3 
,uncorrected), and showed 5.17% mean methylation beta difference between two groups. This component 
was positively associated with GM components 1,2,3,5 and 7, and negatively associated with GM 
components 4,6 and 8 after multiple comparisons correction, as listed in Table 2. These GM-methylation 
associations remained significant after controlling for diagnosis or in SZ group only (Table S8),  
suggesting that the GM-methylation relationship is more general rather than driven by the disease. The 
interaction between methylation component 1 and diagnosis was significant in four pairs of GM-
methylation components with stronger correlation in the patient group than in the HC group (Fig.S3 and 
Table S5), likely reflecting larger variations (e.g., much lower loadings in the GM and methylation 
components) only observed in patients.  
Methylation components 2 and 3 were the ones linked to the SNP components aforementioned, 
and also significantly associated with GM component 9, mainly located at cerebellum, thalamus and 
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caudate (R2=0.038, and 0.056; p=0.05 and 8.7×10-3, respectively). Although connected to the same GM 
component, increasing GM in the component 9 regions was associated with decreased loadings of 
methylation component 2, and increased loadings of methylation component 3.  
With respect to medication and symptoms, no significant effects were observed on the three 
methylation and nine GM components using the threshold FDR≤0.05 in SZ patients. However, significant 
associations were found between methylation component 1 with the working memory score (R2=0.053, p 
=1.27×10-3) and the TOL score (R2=0.023, p=0.04). Seven out of eight GM components related to the 
methylation component 1 were also significantly associated with the working memory score while four of 
them were related to the TOL score after correcting for multiple testing (Table S7). 
In the replication data, we replicated significant correlations between methylation component 1 
and five GM components 1,2,3,5,7 (Table S6).The correlations remained significant after controlling for 
diagnosis(p<0.05) and in SZ group only (Table S8).  We also replicated the associations of GM 
components 1,2,4,7 with the working memory score and GM components 1,2,5,7 with the TOL score 
(p<0.06; Table S7). GM components 1,2,3,7 showed significant group differences with the same direction 
of GM changes as in the discovery data, indicating reduced GM in SZ patients on the corresponding brain 
regions. The correlations between methylation components 2 and 3 with the cerebellum GM component 
were not significant in the replication data (p=0.15), but showed similar effects in HC group (R2 =0.05, p 
= 0.027). 
Three-way link of SNP, DNA methylation and GM  
There was no significant association between SNP components and GM components in both datasets. 
However, the SNP component linked to methylation component 3 (the second SNP-methylation pair) was 
also marginally associated with GM component 9 (p=3.38×10-4, uncorrected). A mediation test showed 
that methylation component 3 significantly mediated the SNP component’s effect on GM component 9 
(average mediation effect = 0.0039, the proportion of SNP effect mediated: 23.63%, p=0.02).  
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Discussion and conclusions 
In this work, we observed, in blood and saliva samples, two pairs of significantly related SNP-
methylation components by multivariate analysis. The correlations were consistent in both SZ and HC 
groups and mainly contributed by cis-meQTLs (Fig.S1), suggesting that such intrinsic SNP-methylation 
relationship was driven by the effects of the SNPs on DNA methylation in close proximity, consistent 
with previous findings4,18,31,36. The benefit of identifying component based SNP-methylation correlations, 
instead of individual meQTLs, lies in the fact that multiple SNP or methylation loci can be functionally 
related and be grouped into one factor38. Component analysis not only reduced the number of statistical 
test but also derived a region of interest. The main regions covered by both SNP-methylation component 
pairs (Chr.10 around NT5C2, ARL3, and Chr.3 around ITIH4 respectively) were also identified as 
prominent meQTL regions in previous studies using brain tissues31,36.  
More than 97% of meQTLs were replicated in saliva, and about 20% were also reported in 
studies of brain tissues passing genome-wide significance31,36. We speculated more meQTLs might be 
replicated in brain if less strict significance thresholds were used. Given meQTL has been proposed to 
contribute to cross-tissue similarity30,57, we used data of blood and brain samples from the same 12 
epilepsy subjects29 to test cross-tissue similarity of the identified CpG sites. Two CpG sites(cg00035347 
on NT5C2 and cg10872209 on ARL3) involving the majority of significant cis-effect, showed strong 
blood-brain correspondence with correlation r=0.73 and 0.76, respectively. These findings support that 
the meQTL effects are relatively consistent across tissue types31,36, and likely mediate cross-tissue 
methylation similarity. Hence it is plausible to study effects of this specific set of methylation sites, 
assessed from peripheral tissues, on brain structure in psychiatric disorders17. 
SNP-affected methylation components 2 and 3 in the blood sample were significantly associated 
with one cerebellum GM component, and showed an interesting mediation effect, even though these 
correlations were replicated significantly only in HC group. Although SNP-effect on methylation was 
consistent cross tissues, different types of peripheral tissues may have different surrogate ability for brain. 
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Given the contributing genes of these two components such as ITIH4, NT5C2 have shown expressional 
changes in brain tissues in SZ patients (p=0.0025 and 0.01 respectively)58, we speculate these methylation 
components are somewhat relevant to GM in brain. This hypothesis warrants further investigation using a 
larger sample.   
Methylation component 1 from the gene coding for nitric oxide synthase interacting protein 
(NOSIP) was significantly associated with five GM components in both datasets. Further examination 
found a significant negative blood-brain correlation of the CpG site cg05696092 (r=-0.63)29. Considering 
that there was no meQTL identified on this site, a negative cross-tissue correlation suggests another 
mechanism, more likely environment-related, which may underlie the cross-tissue similarity as negative 
correlations were also observed in another study59. The site cg05696092 was located in the promoter 
region of NOSIP and was hypomethylated in blood and saliva samples of SZ patients, suggesting 
hypermethylation in brain of SZ. Testing for the change of NOSIP gene expression in brain showed 
significant decreased expression in SZ patients58, suggesting the hypermethylation may repress NOSIP 
expression. The protein encoded by the gene NOSIP mainly sequesters and inhibits the activity of nitric 
oxide synthase (NOS) and reduces nitric oxide (NO) production60,61. Several studies have found higher 
levels of NOS expression or NO in subjects with psychiatric disorders cross brain including the frontal 
cortex62,63, caudate64, hippocampus65 and cerebellum66. Additionally, NO or NOS have been shown to 
relate to neural cell apoptosis, synaptic plastic and remodeling, neurodegeneration, and the development 
of neuronal structures67-69. Taken together, we speculate that hypermethylation in the promoter of the 
NOSIP gene induces a decrease of NOSIP expression and an increase of NO production in the brain of 
patients, and further affects neuron activity which may be partially reflected by GM signal. 
 No significant SNP-GM associations were detected, and no SNP component showed group 
difference, perhaps due to the small sample size. Even though we focused on 108 SZ-risk regions, genetic 
effects on the brain may not be as large as expected36. In contrast, methylation component 1 showed 
altered methylation level in SZ in both datasets, and its associated four GM components also had 
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replicated group differences. The most significance GM density reduction included frontal, temporal, and 
cerebellum regions, and an increase of GM from small regions of pre/post-central gyri, consistent with SZ 
brain structural abnormalities reported in a meta-analysis54. Additionally, cognitive ability presented 
replicated, strong relation with GM components in various regions. Methylation in NOSIP also showed an 
interesting relationship with GM components, though it was not replicated. Thus, regarding the 
relationship between SZ and cognition, our data suggest that GM measures show strong association, 
followed by methylation, and no SNP association.  
The findings of this study should be interpreted with consideration of several limitations. First, 
methylation assay in the discovery data only covers promoter regions, which significantly limits our 
discovery power. Although the replication data have much higher coverage, we chose to use it to replicate 
our findings. Secondly, we were unable to confirm the methylation measures via a different platform. 
However, some publications70,71 have reported high reproducibility of Illumina array for DNA 
methylation assay, in line with our own test-retest stability (Spearman rank correlation: 0.96-0.99). 
Furthermore, we used an independent cohort from a different tissue to replicate the identified 
associations, strengthening the credibility of our findings. Thirdly, DNA from whole blood reflects a 
mixture of cell types. The estimated cell type proportion from blood53 was correlated with methylation 
components 2 and 3 but did not alter the significance of the association findings. Fourthly, except alcohol 
abuse or dependence, other substance uses or comorbidities in SZ may have influence on epigenetics or 
GM. We tested the effect of nicotine use and further top 8 PCs of methylation data as surrogate of other 
potential confounding factors, and no significant change on the findings was observed. Finally, the 
findings in this study were mainly built on correlation analyses. We specifically intended to identify SNP-
methylation associations, and then explore their effects on GM which could be further linked to the 
disease. While these associations suggest underlying biological pathways for SZ, we are unable to assess 
a causal relationship among the features. Other ICA-based methods (e.g., three-way parallel ICA72) can 
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be applied to the analysis of more than two modalities, but these methods may not optimally estimate the 
hierarchical relationship.  
In summary, we first identified cross tissue SNP-methylation relationships within the known 
genetic SZ-risk regions, which were largely driven by cis-meQTL effects. We also found significant 
associations between methylation and GM components as well as SZ diagnosis in both blood and saliva 
tissues. These findings support a plausible mechanism of genetic risk to influence brain GM variation 
through epigenetic mediation. Furthermore, we identified cross-tissue similarities of methylation patterns 
unlikely to be regulated by SNP variants. Methylation-brain associations either regulated by SNPs or 
other factors, suggest the integral role epigenetics plays on brain structural variation and in the 
pathogenesis of SZ conveyed by both genetic and environmental influences.
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Figure legends 
Figure 1. The analysis flow of the study. 
Figure 2. (A) and (C) show meQTL mapping of the contributing SNPs and methylation sites (|z|>=2.5) in 
both pairs of significantly linked SNP and DNA methylation components. (B) and (E) plot their loadings 
with correlations r=0.48 and 0.35, shown separately by HC and SZ groups. (C) and (F) give examples of 
the strongest meQTL in each pair (located on chr.10 around gene NT5C2 and chr.3 around gene ITIH4, 
respectively). 
Figure 3. Brain mapping of nine GM components significantly associated with three methylation 
components. (A) Seven GM components have significant group differences while the other two in (B) 
show no significant differences.  
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Table 1. Demographic of participants in the both discovery and replication data 
Variables Discovery data (n=202) Replication data (n=192) 
SZ 
(Schizoaffective/Schizophreniform) 
HC SZ 
(Schizoaffective/Schizophreniform) 
HC 
Diagnosis 92  
(1/4)  
110 93  
(11/0) 
99 
Gender* 
(women, %) 
26.09 37.27 14.13 28.28 
Age, y (SD) 34.14 (10.23) 32.66 (10.91) 37.96 (14.33) 37.09(12.16) 
Race* 
(White/Black/
Asian/Other) 
70/15/3/4 99/3/4/4 42/7/0/44 51/6/0/42 
Alcohol 
depend/abuse 
27 0 0 0 
* indicates significant differences between SZ and HC. The differences were controlled or corrected in the analyses.  
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Table 2. The relationship between GM and DNA methylation components in the discovery data  
Methylation 
components 
Associated gray matter imaging components 
No. Methylation-
Diagnosis 
association 
 
Cohen’s d 
(p, direction); 
Significant genes: 
No. Methylation-
GM 
association 
 
R2  
(T-score, p) 
GM-
Diagnosis 
association 
 
Cohen’s d  
(p, direction)  
 
Brain regions (|z|>2.5) L/R 
volume 
(mm3) 
1 -0.348 
(0.009, HC>SZ); 
 
NOSIP 
1 0.1 
(4.77, 
9.1×10-5) 
-0.863 
(7.7×10-8, 
HC>SZ) 
Positive: Superior/middle/medial/inferior 
Frontal Gyri, 
Negative: Precentral/Postcentral Gyri 
8.6/11.8 
 
3.5/0.8 
2 0.11 
(5.02 ,  
3.8×10-5) 
-0.79 
(5.6×10-7, 
HC>SZ) 
Positive: Superior/middle/inferior Temporal 
Gyri, 
7.7/7 
3 0.078  
(4.11 , 
9.7×10-4) 
-0.551 
(4.9×10-4, 
HC>SZ) 
Positive: Inferior Semi-Lunar Lobule,  
Uvula,  
Pyramis, 
3.2/2.6, 
1.0/1.0, 
1.3/1.4 
4 0.071 
(-3.89 , 
2.0×10-3) 
0.532 
(5.7×10-4, 
HC<SZ) 
Positive: Lingual Gyrus,  
Negative: Inferior/middle Frontal Gyri, 
Lingual Gyrus,  
Insula 
2.6/1.5, 
1/1.6, 
1.0/0.2, 
0.3/0.6 
5 0.13  
(5.45 , 
1.5×10-5) 
-0.418 
(7.5×10-3, 
HC>SZ) 
Positive: Lingual Gyrus,  
Cuneus,  
Superior/Middle/inferior Occipital Gyri, 
Precuneus 
1.7/2.0, 
3.9/4.6, 
4.9/4.6, 
0.9/1.8 
6 0.098  
(-4.65 , 
1.2×10-4) 
0.401 
(9.4×10-3, 
HC<SZ) 
Positive: Insula,  
Precentral/Postcentral Gyrus, 
Negative: Inferior Parietal Lobule,  
Cingulate Gyrus,  
Superior/Middle temporal gyri  
2.3/2.1, 
1.2/1.4, 
0.4/0.4, 
1.7/2.0, 
0.4/0.7 
7 0.11  
(5.07 , 
4.5×10-5) 
-0.353 
(0.02, 
HC>SZ) 
Positive: Superior/Middle/Inferior Temporal 
Gyri,  
Middle/Inferior Frontal Gyri 
5.5/4.7,  
 
0.6/0.4 
8 0.05 
(-3.25 , 
0.015) 
0.024 
(non-
significance) 
Positive: Superior/Middle Temporal gyri, 
Supramarginal Gyrus,  
Superior/Inferior Parietal Lobule,  
Precuneus 
3.6/2.7, 
0.6/0.8, 
1.4/2.1, 
0.5/0.3 
2 -0.211 
(0.12, HC>SZ);  
NT5C2, CSMD1, 
FES, ARL3 
 
 
 
9 
0.038  
(-2.82 , 
0.05) 
 
 
-0.091 
(non-
significance) 
 
Positive: Declive,  
Pyramis,  
Vermis,  
Culmen,  
Thalamus, 
Caudate 
 
1.4/1.5, 
0.6/0.7, 
0.5/0.5, 
1.7/1.6, 
0.3/0.6, 
1.1/1.3, 
3 -0.296 
(0.06, HC>SZ); 
ITIH4 
0.056 
(3.44 , 
8.7×10-3) 
 
 
